PharmaTimes - October 2019

More patients than ever before consider clinical research as a legitimate care option, and, despite the threat of an uncertain Brexit, the UK continues to be viewed as one of the best countries in the world to carry out research. In our cover feature (p27), John Pinching considers the path of clinical research, both past and future, and the significance of the emerging ‘parity between the probed and the probers’.

On page 34, there’s an interesting take on the rise of life science ecosystems. Advances in information technology over the last two decades are fuelling a shift away from the era of large corporations thriving on in-house R&D and towards the formation of loosely coupled life sciences networks with innate ability to adapt within a constantly changing competitive environment.

Elsewhere, flying the flag for social responsibility, Gilead’s Alex Kalomparis (p20) emphasises the role of pharma beyond healthcare, outlining the need for the sector to ensure that it actively supports and encourages change-makers, with longevity and the next generation in mind.

Finally, PharmaTimes is excited to announce the launch of the 2020 International Clinical Researcher of the Year competition, which is now open for entry. The competition, now in its 21st year, offers a wonderful opportunity to benchmark skills against the best in the field and stay up to date with the latest industry trends. Also of note, there’s still time to enter the 2019 PharmaTimes Medical and Scientific Excellence Awards! For more information, visit www.pharmatimes.com/competitions.

I hope you enjoy the issue!

October 2019 - magazine highlights

Turning the tide

Paul Midgley, of Wilmington Healthcare, explores the NHS’...

Driving change

Gilead Sciences’ Alex Kalomparis says pharma has a role to...

Opening doors

China’s pharmaceutical market increasingly offers opportun...

Advancing patient engagement

Neil McGregor-Paterson explores whether health technology...

Trial blazers

Amid the chaos of Brexit, pioneering clinical research con...

Embracing biosimilars

ICON’s Ioannis Katsoulis, Axel Svedbom, Larushka Mellor an...

Ecosystems – the new networks of global innovation

Great science is increasingly the product of a web of inte...

Cloud and connectivity: the formula for saving the NHS?

A cloud-based health service will be key in delivering the...

Cancer vaccines – a new promise?

Dr Stephen Huang and Mr James Huang take a look at the  pr...

Smart People: Elaine Irving

PharmaTimes talks to Elaine Irving on the merits of real-w...

Patient Files: cavernoma

Matt and Emma Chappell’s son Oliver has cavernoma. They ta...